This year has been the year for radiopharmaceuticals, with market projections estimating to grow to $39 billion by 2032. More patients are being treated by Pluvicto and Lutathera than ever before, companies advancing their pipelines across a range of targeting moieties, radioisotopes and novel targets including DLL3 and NTSR1- and that’s not to mention the flood of billion-dollar acquisitions and investments from Novartis, AstraZeneca, Eli Lilly and BMS strengthening the field! The 6^th Targeted Radiopharmaceuticals Summit Europe is the longest standing industry focused meeting delivering an end-to-end overview of this highly competitive and dynamic landscape.

Uncovering novel target development beyond validated PSMA and SSTR2 to reach more indications, expanding targeting moieties to enhance tumour penetration and revealing key case studies from designing a first in human radiopharmaceutical trial as well as applying dosimetry to optimize dosing. The community will explore how Europe can keep up with fast paced innovation by reaching regulatory clarity while analysing the US-Europe intersection across pressing clinical and supply chain challenges to keep your global trials moving. Bringing together insights from the leading radiopharmaceutical minds across pharma, biotech, academia, and clinicians from discovery, preclinical, clinical, CMC and supply chain this is your opportunity to network and learn from the experts.

Gathering world-class speakers to address the most exciting opportunities and challenges spanning novel targeting mechanisms, alpha vs beta emitters, nuclear medicine clinical expertise, isotope supply, European logistics chains as well as pricing and reimbursement- don’t miss the biggest edition of the 6^th Targeted Radiopharmaceuticals Summit to date!